Anmeldung erfolgt in Kürze...
Details werden geladen...
Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN | The Manila Times
This recommendation represents an important step towards improving access for Canadians living with rare kidney diseases
Ähnliche Seiten
Kroll Bond Rating Agency Issues "Positive” Ratings Outlook for Dime Commercial Bancshares, Inc. | The Manila Times
https://www.manilatimes.net/2026/06/17/tmt-newswire/globenewswire/kroll-bond-rating-agency-issues-positive-ratings-outlook-for-dime-commercial-bancshares-inc/2367099
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) | The Manila Times
https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/pasithea-therapeutics-announces-orphan-drug-designation-by-fda-of-pas-004-for-treatment-of-amyotrophic-lateral-sclerosis-als/2356666Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 | The Manila Times
https://www.manilatimes.net/2026/06/13/tmt-newswire/globenewswire/belite-bio-completes-rolling-submission-of-new-drug-application-to-us-food-and-drug-administration-for-tinlarebant-for-the-treatment-of-stargardt-disease-type-1/2364769JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/jascayd-nerandomilast-approved-in-japan-advancing-global-access-to-a-new-ipf-and-ppf-treatment/2345863Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | The Manila Times
https://www.manilatimes.net/2026/06/04/tmt-newswire/globenewswire/iovances-amtagvi-lifileucel-granted-approval-for-the-treatment-of-advanced-melanoma-in-australia/2358282